HCW Biologics targets 1H 2027 IND filing for pancreatic cancer T-cell engager HCW11-018b The purchase of approximately $430,000 by management does not change the fundamentals, but it does signal alignment and makes it less likely that the story is purely narrative without substance.
Market Data 
Markets 
AI
